A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That Were Previously Enrolled in AK002-016 or AK002-012 Studies and Have Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
Latest Information Update: 22 Apr 2024
At a glance
- Drugs Lirentelimab (Primary)
- Indications Eosinophilic gastroenteritis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Allakos
- 14 Sep 2023 Status changed from active, no longer recruiting to completed.
- 10 May 2023 Planned End Date changed from 1 Mar 2023 to 1 Jul 2023.
- 10 May 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Jul 2023.